Stevanato Group SpA (STVN) Q1 2026 Earnings Call Transcript

Why It Matters

The results underscore the accelerating demand for high‑value injectable delivery systems and validate Stevanato’s shift toward higher‑margin products, shaping the competitive landscape for pharma packaging providers.

Key Takeaways

• Revenue €273.6m, +10% constant currency, led by BDS.
• High‑value solutions up 17%, now 47% of revenue.
• Engineering revenue down 31%, margins improve 460 bps.
• Adjusted EBITDA €65.5m, margin 23.9%, up 14%.
• Capital spending €67.6m expands cartridge capacity for 2027.

Pulse Analysis

The injectable drug market is undergoing a structural shift as biopharma firms prioritize sub‑cutaneous delivery for GLP‑1 therapies, obesity treatments, and emerging biologics. Stevanato’s EZ‑fill platform, which offers ready‑to‑use syringes, cartridges and vials, aligns with this trend by reducing contamination risk and simplifying fill‑finish operations. By expanding high‑value syringe capacity in Latina and launching a new cartridge line in Piombino Dese, the company positions itself to capture the growing demand for flexible, high‑potency delivery formats across both established and niche biotech customers.

Financially, Stevanato delivered a solid top‑line performance, with adjusted EBITDA rising 14% to €65.5 million and gross profit margin expanding to 27.5%. The BDS segment’s mix shift toward premium syringes lifted profitability, while the Engineering division, despite a steep revenue drop, showed margin resilience thanks to operational right‑sizing and a more favorable labor cost structure. However, the quarter was not without headwinds: higher depreciation from new plant ramp‑ups, foreign‑currency pressure, and inflationary energy and logistics costs dented overall margin expansion. The company’s disciplined capital allocation—€67.6 million in capex focused on growth assets—demonstrates a commitment to long‑term capacity building while maintaining sufficient liquidity.

Looking ahead, Stevanato’s guidance for 2026 remains unchanged, forecasting revenue between €1.26 billion and €1.29 billion and adjusted EBITDA up to €346.9 million. The firm’s strategic emphasis on high‑value, ready‑to‑use solutions, coupled with contractual GLP‑1 volume commitments, provides a predictable revenue runway. Investors should monitor the rollout of the new cartridge lines and the company’s ability to translate capacity expansions into sustained order intake, especially as the biopharma sector continues to shift toward larger‑volume, home‑based injectable therapies.